Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers

References

• Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2004;98–117. doi:10.1182/asheducation-2004.1.98
   Google Scholar
• Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013;88:318–327. doi:10.1002/ajh.2340423526416
   PubMed Web of Science ®Google Scholar
• Sill H, Olipitz W, Zebisch A, et al. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol. 2011;162:792–805. doi:10.1111/j.1476-5381.2010.01100.x21039422
   PubMed Web of Science ®Google Scholar
• Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11:275–286. doi:10.1007/s40258-013-0032-223677706
   PubMedGoogle Scholar
• Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118(19):5084–5095. doi:10.1182/blood-2011-02-33487021881045
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15:3325–3332. doi:10.1158/1078-0432.CCR-08-301019417016
   PubMed Web of Science ®Google Scholar
• Nasreldin E, Safwat DM, Hamed HB, et al. T-regulatory and T-helper type17 cells associated cytokines (IL-35, IL-17) as potential diagnostic and prognostic biomarkers in egyptian acute myeloid leukemia patients. J Clin Cell Immunol. 2016;7:478. doi:10.4172/2155-9899
   Google Scholar
• Yang W, Xu Y. Clinical significance of Treg cell frequency in acute myeloid leukemia. Int J Hematol. 2013;98(5):558–562. doi:10.1007/s12185-013-1436-324142765
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Mizoguchi I, Chiba Y, et al. Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family. Front Immunol. 2016;7:479. doi:10.3389/fimmu.2016.0047927867385
   PubMed Web of Science ®Google Scholar
• Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722–728. doi:10.1038/ni.236622814351
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Chiba Y, Furusawa J-I, et al. Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci. 2015;106(9):1103–1110. doi:10.1111/cas.1273126132605
   PubMed Web of Science ®Google Scholar
• Li MS, Liu Z, Liu JQ, et al. The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy. 2015;7(2):191–200. doi:10.2217/imt.14.9525713993
   PubMed Web of Science ®Google Scholar
• Diakowska D, Lewandowski A, Markocka-Mączka K, et al. Concentration of serum interleukin-27 increase in patients with lymph node metastatic gastroesophageal cancer. Adv Clin Exp Med. 2013;22:683–691.24285453
   PubMed Web of Science ®Google Scholar
• Gonin J, Carlotti A, Dietrich C, et al. Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas. PLoS One. 2013;8:e75694. doi:10.1371/journal.pone.007569424130734
   PubMed Web of Science ®Google Scholar
• Lu D, Zhou X, Yao L, et al. Clinical implications of the interleukin 27 serum level in breast cancer. J Investig Med. 2014;62:627–631. doi:10.2310/JIM.0000000000000046
   Web of Science ®Google Scholar
• Larousserie F, Bardel E, Pflanz S, et al. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol. 2005;166:1217–1228. doi:10.1016/S0002-9440(10)62340-115793300
   PubMed Web of Science ®Google Scholar
• Collison LW, Chaturvedi V, Henderson AL, et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol. 2011;187:462–471. doi:10.4049/jimmunol.110096721613618
   PubMed Web of Science ®Google Scholar
• Workman CJ, Brown SA, Rehg JE, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11:1093–1101. doi:10.1038/ni.195220953201
   PubMed Web of Science ®Google Scholar
• Tao Q, Pan Y, Wang Y, et al. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int J Cancer. 2015;137:2384–2393. doi:10.1002/ijc.2956325866142
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Chapter 98: acute leukemias in adults In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, editors. Abeloff’s Clinical Oncology. 5th ed. Philadelphia (PA): Elsevier; 2014.
   Google Scholar
• Kebriaei P, de Lima M, Estey EH, et al. Chapter 107: management of acute leukemias In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2015.
   Google Scholar
• Khaled SA, Burthem J, Abo ElNoor E, et al. Differences between nucleophosmin isoforms in de-novo acute myeloid leukemia: possible implications in developing targeted therapy for acute myeloid leukemia with normal karyotype. Egypt J Hematol. 2015;40(41):190–194. doi:10.4103/1110-1067.170220
   Google Scholar
• Schlenk RF, Döhner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematol`ogica. 2009;94(1):54–60. doi:10.3324/haematol.13378
   PubMed Web of Science ®Google Scholar
• Khaled SA, Burthem J, Abo ElNoor E, et al. Role of nucleophosmin gene mutation in leukemogenesis of acute myeloid leukemia. J Hematol. 2018;7(1):7–13. doi:10.14740/jh365w
   Web of Science ®Google Scholar
• Wang Z, Liu JQ, Liu Z, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013;190:2415–2423. doi:10.4049/jimmunol.120253523345334
   PubMed Web of Science ®Google Scholar
• Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009;23:2233–2241. doi:10.1038/leu.2009.17519727127
   PubMed Web of Science ®Google Scholar
• Zorzoli A, Di Carlo E, Cocco C, et al. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res. 2012;18(6):1630–1640. doi:10.1158/1078-0432.CCR-11-243222383738
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hunter A. The immunobiology of interleukin27. Annu Rev Immunol. 2015;33:417–443. doi:10.1146/annurev-immunol-032414-11213425861977
   PubMed Web of Science ®Google Scholar
• Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):150. doi:10.1186/s13045-017-0516-x28821272
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa140722225317870
   PubMed Web of Science ®Google Scholar
• Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91(10):1400–1404.17018393
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485. doi:10.1182/blood-2005-09-372416455952
   PubMed Web of Science ®Google Scholar
• Wu H, Li P, Shao N, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-Î2 in acute myeloid leukemia. Oncol Lett. 2012;3:1119–1123. doi:10.3892/ol.2012.61422783403
   PubMed Web of Science ®Google Scholar
• Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4⺠CD25⺠CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129:1373–1381. doi:10.1002/ijc.2579121105040
   PubMed Web of Science ®Google Scholar
• Ersvaer E, Liseth K, Skavland J, et al. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC, TH, TH17 and TREG cells. BMC Immunol. 2010;9:11–38.
   Google Scholar
• Wang R-X, Yu C-R, Dambeza IM, et al. Interleukin-35 induces regulatory B-cells that suppress autoimmune disease. Nat Med. 2014;20:633–641. doi:10.1038/nm.355424743305
   PubMed Web of Science ®Google Scholar
• Shen P, Roch T, Lampropoul V, et al. IL35 producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;567:366–370. doi:10.1038/nature12979
   Web of Science ®Google Scholar
• Zweig MH, Camphell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577.8472349
   PubMed Web of Science ®Google Scholar
• Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285–1293. doi:10.1126/science.32876153287615
   PubMed Web of Science ®Google Scholar